Experts discuss the importance of NGS testing for identifying actionable alterations like RET fusions in solid tumors and when to consider testing.
Back
My Treatment Approach: Targeting Genetic Alterations in Tumors: Clinical Scenarios and Precision Oncology Approaches
Insights into integrating tumor agnostic therapies for actionable genetic alterations across solid tumors. Renowned experts Dr. Vivek Subbiah, Dr. Karisa Schreck, and Dr. Rimas Lukas delve into pivotal clinical cases showcasing the identification and targeted treatment of BRAF and RET fusions. The in-depth discussion spotlights practical strategies for NGS testing, overcoming barriers to adoption, efficacy and safety data from landmark trials, sequencing of therapies, and the evolving landscape of precision oncology beyond current approvals. Gain invaluable clinical pearls for optimizing patient outcomes with tumor agnostic targeted agents in the community setting.
My Treatment Approach: Targeting Genetic Alterations in Tumors: Clinical Scenarios and Precision Oncology Approaches
Episodes
All
All
Dr. Lukas presents a case of a young man with a BRAF-fused brain tumor treated with a MEK inhibitor. Explored tailored therapy targeting the underlying genetic alteration.
Dr. Schreck brings forward a compelling case of a teenage female with BRAF V600E mutant ganglioglioma. Witness how the identification of this specific genetic alteration paved the way for treated with targeted therapy.
Experts discuss the challenges in adopting targeted therapies like BRAF/MEK inhibitors for BRAF-altered gliomas and gangliogliomas and strategies to facilitate their integration into practice.
Dr. Subbiah and Dr. Lukas review the efficacy and safety data from key clinical trials like ROAR and MATC evaluating tumor agnostic therapies across different tumor types.
Dr. Subbiah presents a pancreatic cancer case with PRKARA1A- RET fusion treated with selpercatinib in a clinical trial.
The panel discusses the impact of tumor agnostic approvals like BRAF/MEK inhibitors on the treatment landscape, unmet needs address and sequencing therapies like RET inhibitors in cancers like pancreatic cancer.
The panelists provide their perspective on best practices for keeping up with the rapidly evolving RET fusion landscape and unmet needs to be addressed by future RET-targeted therapies beyond lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
3
Five Under 5: Top Oncology Videos for the Week of 8/2
4
Revisit Every OncLive On Air Episode From July 2026
5